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Although the majority of primary HIV-1 variants can be neutralized by broadly neutralizing antibodies such as b12, 2G12, 2F5 and 4E10,
resistance to these antibodies has been reported as well. The ability of the broadly neutralizing antibodies to inhibit a variety of viruses suggests
that their epitopes are conserved and escape from these antibodies may thus come at a cost to viral fitness. Here we demonstrate that resistance to
broadly neutralizing antibodies was in general not associated with a reduced replicative capacity of the virus in vitro. This indicates that loss of
replicative capacity due to escape from broadly neutralizing antibodies may be limited.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Escape; Broadly neutralizing antibodies; Replicative capacityIntroduction
The envelope glycoprotein of human immunodeficiency
virus type 1 (HIV-1) is exposed at the viral surface and is the
target for neutralizing antibodies (Parren et al., 1999; Poignard
et al., 2001). Primary virus isolates are relatively resistant to
neutralization by antibodies directed to the envelope glycopro-
tein. Most primary HIV-1 isolates, however, can be neutralized
by the four broadly neutralizing monoclonal antibodies (mAbs),
b12, 2G12, 2F5 and 4E10 (Binley et al., 2004; Burton et al.,
1994; Conley et al., 1994b; Moore et al., 1995; Parren et al.,
1998; Trkola et al., 1995; Zwick et al., 2001), although addi-
tional mAbs of somewhat more limited neutralization breadth
have also been described (e.g. 447-52D (Conley et al., 1994a),
IgG1 X5 (Moulard et al., 2002), D5 (Miller et al., 2005)).⁎ Corresponding author. Fax: +31 20 512 3310.
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doi:10.1016/j.virol.2007.02.011Neutralizing antibodies can be detected early in HIV-1
infection within 2 months after seroconversion (Albert et al.,
1990; Montefiori et al., 2001; Moog et al., 1997; Parren et al.,
1999; Pilgrim et al., 1997; Richman et al., 2003; Wei et al.,
2003). Neutralizing activity of autologous serum against
contemporary viruses is often low, suggesting that these viruses
have escaped from humoral immune pressure and that
neutralizing antibodies are functional in infected individuals
(Albert et al., 1990; Arendrup et al., 1992; Bradney et al., 1999;
Montefiori et al., 2003; Trachtenberg and Sande, 2002;
Tremblay and Wainberg, 1990; Wei et al., 2003).
In newly HIV-1 infected individuals, a relatively neutraliza-
tion sensitive virus population is assumed to be responsible for
the primary infection (Derdeyn et al., 2004) although the
enhanced neutralization sensitivity of recently transmitted HIV-
1 was not confirmed by others (Frost et al., 2005). After dev-
elopment of a neutralizing antibody response in the infected
patient, viruses with escape mutations will be rapidly selected,
resulting in a relatively neutralization resistant virus population
(Richman et al., 2003; Wei et al., 2003). This would imply that,
in the absence of neutralizing antibodies, neutralization sensitive
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resistant viruses, which might be caused by an increased
replicative capacity of the neutralization sensitive virus variants
as compared to the resistant variants. Primary HIV-1 variants
display differential neutralization sensitivity for broadly neu-
tralizing antibodies (Quakkelaar et al., submitted for publica-
tion). As broadly neutralizing antibodies are considered to be
directed at conserved epitopes, escape mutations in these
epitopes may be associated with even larger changes in repli-
cative capacity.
Here we studied the replication kinetics of HIV-1 variants
isolated at different time points during infection from 6 patients
and subsequently analyzed the potential relationship between




We previously showed differential sensitivity of primary
HIV-1 variants (n=55) obtained at different time points in the
course of infection from 4 recipients of homosexual transmis-
sion and 2 recipients of parenteral transmission to neutralization
by the 4 broadly neutralizing antibodies IgG1b12, 2G12, 2F5
and 4E10 (Quakkelaar et al., submitted for publication). The
differential neutralization sensitivity was even observed bet-
ween coexisting clonal virus variants for a single antibody.Fig. 1. Replicative capacity of viruses isolated at sequential time points after homos
variants (circles) and late variants (triangles) is plotted against the day of culture. O
determination of replicative capacity 2*106 PHA-stimulated PBMC were inoculated
37 °C in a shaking water bath. P24 antigen production in culture supernatant that wasGiven the high level of genetic homology between these
coexisting HIV-1 variants, they provide a unique tool to study
the relationship between viral replicative capacity and neutra-
lization sensitivity. Replication kinetics were determined during
a period of 18 days after inoculation of PHA-stimulated PBMC
with equal viral inocula (100 TCID50 per culture). Replication
rates varied between viruses obtained from a single individual,
and even between viruses obtained from the same time point. As
we reported previously (Blaak et al., 1998a), viruses isolated
early in infection after homosexual transmission tended to have
slower replication kinetics compared to viruses isolated later in
infection, which was significant in patient ACH658 at multiple
time points in the viral replication assay (P=0.04; Fig. 1A).
HIV-1 variants isolated at sequential time points after parenteral
transmission showed similar replication kinetics (data not
shown). However, the time between the moments of virus
isolation in these parenteral recipients may be too short to
observe differences in replication rates (<8 months of follow-up
for parenteral compared to >4 years for homosexual transmis-
sion cases).
ACH9012 was infected with both R5 and X4 viruses. P24
production of R5 and X4 viruses is shown in Fig. 1B. R5 viruses
showed lower replication kinetics than coexisting X4 viruses
relatively early in infection (P=0.03). This difference was
less pronounced for viruses that were isolated 8 months later
(P=0.05).
The lower replication rate of viruses isolated early in
infection as compared to viruses isolated late in infection seemsexual transmission (A) and parenteral transmission (B). P24 production of early
pen symbols represent R5 variants, closed symbols represent X4 variants. For
with 100 TCID50 of a given HIV-1 variant in a total volume of 1 ml for 2 h at
harvested each day was determined in one in-house p24 antigen capture ELISA.
Fig. 2. Replication kinetics of viruses that were sensitive (circles) or resistant (triangles) to neutralization by b12, 2G12, 2F5 and 4E10. Mean p24 production of
average values per patient values and standard deviations are indicated.
Table 1
Correlation between replicative capacity and neutralization sensitivity (Pearson
correlations are indicated)
Individual IC50 b12 IC50 2G12 IC50 2F5 IC50 4E10
ACH1140 n=5 0.472 0.396 0.911¶ 0.039
ACH658 n=7 0.884* −0.872§ −0.480 0.734
ACH1161 n=8 0.043 −0.263 NA −0.730$
F n=17 −0.026 NA −0.448 −0.108
p127 n=11 −0.323 0.820# 0.163 NA
ACH9012 n=6–7 −0.084 −0.693 −0.586 −0.833$
NA, not applicable. IC50 value is constant. *P=0.008;
§P=0.01; ¶P=0.03;
$P=0.04; #P=0.001.
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virus variants with high replication kinetics would be
responsible for the primary infection (Derdeyn et al., 2004).
In our study, the earliest viruses available after homosexual
transmission were isolated 3 weeks after seroconversion which
makes it unlikely that these viruses were slowly replicating due
to adaptation to host immune responses since autologous
neutralizing antibodies are absent this early in infection
(Richman et al., 2003; Wei et al., 2003). To further address
this issue, we determined the dynamics of viral replication early
in infection using virus clones isolated at several time points
within the first 2 months after seroconversion upon homosexual
transmission from an individual with acute infection. Replica-
tion rates of these viruses were low and did not change within
the first 2 months after seroconversion (data not shown). In
summary, viruses isolated early in infection from recipients of
homosexual transmission tended to have slow replication rates
which increased during long-term infection.
Viral replication kinetics in relation to sensitivity to broadly
neutralizing antibody neutralization
As stated above, we previously determined the neutralization
sensitivity of the viruses in our study for the broadly
neutralizing antibodies b12, 2G12, 2F5 and 4E10 (Quakkelaar
et al., submitted for publication). We next determined whether
HIV-1 replication kinetics and neutralization sensitivity for the
broadly neutralizing antibodies are indeed correlated. Replica-
tion kinetics of neutralization sensitive and resistant viruses
obtained from recipients of homosexual transmission are shown
in Fig. 2. Viruses were considered neutralization sensitive when
the IC50 value for the broadly neutralizing antibody was lowerthan 12.5 μg/ml. Replicative capacity was not different between
viruses that were resistant or sensitive to neutralization by 4E10.
Viruses resistant to b12 neutralization tended to have higher
replication kinetics than viruses that were sensitive to b12
neutralization (P=0.08). In contrast, viruses that were sensitive
to 2G12 and 2F5 neutralization replicated faster than resistant
viruses (P=0.01 and P=0.04, respectively). Replication
kinetics of neutralization resistant and sensitive viruses obtained
from recipients of parenteral transmission were not different
(data not shown).
We subsequently studied whether the level of virus
replication was correlated with the level of viral neutralization
sensitivity for individual virus variants from each patient. We
calculated Pearson correlations between IC50 values of
IgG1b12, 2G12, 2F5 and 4E10 for a given virus variant and
the gag p24 production in culture medium on the average day of
maximum virus production (day 15) of the replication assay
performed with that same virus variant. Pearson correlations are
indicated in Table 1. When only 2 virus variants were studied,
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of 6 patients showed a negative correlation between replication
rate and neutralization sensitivity for one of the antibodies
(ACH658, ACH1161 and ACH9012 for antibodies 2G12, 4E10
and 4E10, respectively). However, 3 of 6 patients showed a
positive correlation between replication and neutralization for
one of the antibodies (patients ACH658, ACH1140 and p127 for
antibodies b12, 2F5 and 2G12 respectively).
In conclusion, reduced replicative capacity was not a general
feature of neutralization resistant virus variants. However,
negative correlations were observed for some viruses from
some patients.
Discussion
It is generally accepted that a vaccine against HIV-1 should
elicit broadly neutralizing antibodies to provide sterilizing
immunity. To date, only 4 such antibodies (b12, 2G12, 2F5 and
4E10) have been identified although additional mAbs of
somewhat more limited neutralization breadth have also been
described (Binley et al., 2004; Burton et al., 1994; Conley et al.,
1994a,1994b; Miller et al., 2005; Moore et al., 1995; Moulard et
al., 2002; Parren et al., 1998; Trkola et al., 1995; Zwick et al.,
2001). Considering the breadth and reactivity of mAbs b12,
2G12, 2F5 and 4E10, their epitopes are expected to be
conserved between HIV-1 variants (Binley et al., 2004). The
conserved nature of these epitopes suggests that mutations in
HIV-1 that allow escape from these antibodies may come at a
severe cost to viral fitness. In the present study, we determined
for the first time the replication kinetics of viruses from which
we previously established the sensitivity to the broadly
neutralizing antibodies b12, 2G12, 2F5 and 4E10 (Quakkelaar
et al., submitted for publication). Viruses were isolated at
sequential time points in the course of infection from 6 patients.
We observed that replication rates were different between
viruses from different patients as well as between viruses from
the same patient, even between viruses that were isolated from
the same blood sample. Overall, virus variants isolated early in
infection tended to have slower replication kinetics than viruses
isolated later in infection, in agreement with previous observa-
tions by us and others (Blaak et al., 1998a; Kwa et al., 2003;
Repits et al., 2005; Troyer et al., 2005; Van 't Wout et al., 1998).
Apparently, the virus phenotype best adapted to be transmitted
or to replicate and persist in the early asymptomatic phase of
infection coincides with a reduced replicative capacity in vitro.
Probably, during infection, viruses with the highest replication
kinetics are selected which may relate to target cell availability
and (co)receptor expression levels on these target cells.
Overall, we did not observe a correlation between viral
replication kinetics and neutralization sensitivity for the broadly
neutralizing antibodies. In other words, resistance to broadly
neutralizing antibodies did not generally coincide with a
reduction in replicative capacity. However, resistance to 2G12
or 4E10 neutralization of HIV-1 variants from 3 patients was
associated with reduced replicative capacity, whereas resistance
to neutralization by b12, 2G12 or 2F5 was associated with
increased replicative capacity for viruses from 3 patients.In our previous study we noticed that resistance to broadly
neutralizing antibodies was not necessarily associated with
mutations in the respective epitopes (Quakkelaar et al.,
submitted for publication) suggesting a role for mutations
outside the targeted epitopes that influence for instance the
conformation of the epitope. We therefore next compared the
replication kinetics of neutralization sensitive and resistant
viruses that had or did not have substitutions of residues
involved in the epitopes of the broadly neutralizing antibodies
under study (Calarese et al., 2003; Sanders et al., 2002; Scanlan
et al., 2002; Zwick et al., 2005). Mutations in the epitopes for
2F5 and 4E10 did not affect viral replication in vitro. Viruses
that lacked at least one of the five potential N-linked
glycosylation sites (PNGS) involved in 2G12 binding had
higher replication kinetics than viruses with all 5 PNGS present
(P<0.01, Mann–Whitney U test, data not shown). Although the
absence of 1 or more of the 5 PNGS involved in 2G12 binding
does not reflect a lower overall number of PNGS in the viral
envelope, it suggests that fewer PNGS at the specific positions
that contribute to the 2G12 epitope may favor higher replication
rates, for instance by facilitating binding of the virus to the
cellular entry complex. However, a correlation between
replicative capacity and number of PNGS in V1-V5 was not
observed (data not shown).
The fact that from all patients at least some virus variants
could be neutralized by the broadly neutralizing antibodies
supports the idea that these antibodies are directed against
conserved epitopes in the envelope glycoprotein. Alternatively,
these epitopes may be only conserved due to the absence of b12,
2G12, 2F5 and 4E10 like antibodies in most HIV-1 infected
individuals and thus the lack of selection pressure on these
epitopes. Some virus variants studied here were, however,
resistant to neutralization by the broadly neutralizing anti-
bodies, which may imply that neutralizing antibodies directed
against these epitopes are present in these individuals and that
selection against these conserved epitopes does exist in vivo.
Viral replication rate and sensitivity to broadly neutralizing
antibodies may not be associated for the majority of HIV-1
variants. Alternatively, a reduction in viral fitness associated
with escape mutations in this region might be too small to be
detected in the replication assay as we performed here. In
agreement, subtle differences in viral fitness associated with
escape from cytotoxic T lymphocytes (CTL) were also not
detected when replication kinetics were compared and only
observed in direct competition experiments between wild type
and mutant viruses (Martinez-Picado et al., 2006). On the other
hand, fitness differences that are relevant in vivo may be absent
in vitro due to for instance different target cell availability.
Finally, as suggested for CTL escape variants from HIV-1,
neutralization resistant viruses may develop compensatory
mutations by which replicative capacity is ultimately restored.
The reduced replicative capacity of virus variants that were
resistant to some antibodies in 3 patients might be due to the
absence of compensatory mutations.
In this study, we have focused on the association between
replicative capacity and the neutralization resistance of primary
HIV-1 variants to 4 broadly neutralizing antibodies. One could
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sensitivity to neutralization by broadly reactive polyclonal sera
as resistance to a mix of neutralizing antibodies directed against
different epitopes may indeed have more impact on viral fitness.
Some of the viruses in our study, however, were resistant to all 4
broadly neutralizing antibodies tested, yet had replication
kinetics similar to their coexisting neutralization sensitive
HIV-1 variants (data not shown). These data imply that a
vaccine eliciting broadly neutralizing antibodies of this kind
may, when not providing complete sterilizing immunity, select
for HIV-1 escape variants that will maintain optimal replication
capacity, thus not slowing down the pandemic. This observation
supports the need for additional neutralizing antibody specifi-
cities to be elicited by a successful vaccine.
Material and methods
Patients and viruses
Clonal virus variants isolated at sequential time points in the
course of infection from 4 recipients of homosexual transmis-
sion who participated in the Amsterdam Cohort Studies on HIV
infection and AIDS, and from two recipients of accidental or
deliberate parenteral transmission (Lange et al., 1990; Veenstra
et al., 1995) were used in this study (Blaak et al., 1998b; Van 't
Wout et al., 1994). In addition, clonal virus variants isolated
from an individual with primary HIV-1 infection were studied.
Clonal virus variants were previously obtained in multiple
micro co-cultures of limiting amounts of HIV-infected patient
peripheral blood mononuclear cells (PBMC) and phytohae-
magglutinin (PHA)-stimulated PBMC from healthy seronega-
tive blood donors, as described before (Schuitemaker et al.,
1992; Van 't Wout et al., 1994). Virus stocks were prepared on
PHA-stimulated PBMC. The total number of passages was kept
to a minimum as this may change the primary phenotype of the
viruses (Beaumont et al., 2004). Virus production was
monitored using an in-house p24 ELISA (Tersmette et al.,
1989). Upon sufficient virus production, virus stocks were
frozen and the infectious titers of the stocks were quantified by
determination of the 50% tissue culture infectious dose
(TCID50) in PHA-stimulated PBMC.
Cells
PBMC were isolated from buffy coats by Ficoll density
centrifugation. For stimulation, 5*106 cells/ml were cultured
for 2 days in Iscoves Modified Dulbecco's Medium (IMDM)
supplemented with 10% fetal bovine serum (FBS, Perbio,
Logan, Utah, USA), penicillin (100 U/ml, Gibco, Paisly,
Scotland, UK), streptomycin (100 μg/ml, Gibco), cyproxin
(5 μg/ml, Bayer, Mijdrecht, The Netherlands) and PHA
(5 μg/ml, Remel Europe, Dartford, England, UK). Sub-
sequently, PBMC (106/ml) were grown in the absence of
PHA, in medium supplemented with 10 U/ml recombinant
interleukin 2 (rIL2, Cetus Corporation, Emeryville, CA, USA)
and polybrene (5 μg/ml; Hexadimethrine Bromide, Sigma,
Zwijndrecht, The Netherlands).Characterization of HIV-1 replication kinetics
For determination of HIV-1 replication kinetics, 2*106
PHA-stimulated PBMC were inoculated with 100 TCID50 of a
given HIV-1 variant in a total volume of 1 ml for 2 h at 37 °C in
a shaking water bath. Subsequently, cells were washed with 8
ml IMDM containing 10% FBS (Perbio), penicillin (100 U/ml,
Gibco) and streptomycin (100 μg/ml, Gibco) and resuspended
at a concentration of 106 cells/ml for culture. Fresh PHA-
stimulated PBMC (106) in a volume of 0.75 ml were added at
days 5, 8, 11 and 14. Cultures were maintained for 18 days.
Samples (50 μl) for determination of p24 antigen production in
culture supernatant were harvested each day. P24 production in
all samples was determined at the same time using an in-house
p24 antigen capture ELISA. P24 production per ml supernatant
was determined and corrected for the differences in volume of
culture supernatant.
Statistical analysis
Statistical analyses were performed using the Mann–
Whitney U test and Pearson correlations were determined
using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
Statistical significance of differences in replication rate between
viruses isolated early or late in infection or between neutraliza-
tion sensitive and resistant viruses was calculated at each time
point of the virus replication assay and considered significant
when the P value was lower than 0.05 at multiple time points.
Only the P value from the comparison of the last time point is
given. Overall a result was considered statistically significant
when a P value was lower than 0.05.
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